AZN vs KROS
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.
KROS presents a stark dichotomy between a perfect Piotroski F-Score (9/9) and collapsing fundamental growth. While the balance sheet is exceptionally strong with a current ratio of 15.45 and minimal debt, the company is experiencing a severe revenue contraction of -87.30% and extreme operating losses. The stock is significantly undervalued relative to its Graham Number ($28.33) and Intrinsic Value ($16.1), but this value is offset by bearish insider activity and a negative technical trend.
Compare Another Pair
Related Comparisons
AZN vs KROS: Head-to-Head Comparison
This page compares AstraZeneca PLC (AZN) and Keros Therapeutics, Inc. (KROS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.